HeartBeam to Showcase FDA-Cleared Cardiac Technology at JP Morgan Healthcare Conference

HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights, announced its attendance at the JP Morgan 2026 Annual Healthcare Conference scheduled for January 12–15, 2026, at the Westin St. Francis Hotel in San Francisco. Chief Executive Officer Robert Eno and Chief Financial Officer Timothy Cruickshank will be available January 12–14 for off-site meetings with investors and potential commercialization and co-development partners. These discussions are expected to center on the company's recently announced 510(k) clearance from the U.S. Food and Drug Administration for its patented, cable-free 12-lead electrocardiogram synthesis software for arrhythmia assessment, ahead of a planned limited U.S. commercial launch in the first quarter of 2026.

The significance of this announcement lies in the potential transformation of cardiac care delivery through portable technology. HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing these signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is located to deliver actionable heart intelligence. Physicians will potentially be able to identify cardiac health trends and acute conditions and direct patients to appropriate care—all outside of a traditional medical facility—thus redefining the future of cardiac health management.

The FDA clearance represents a critical regulatory milestone for the company's innovative approach. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received clearance in December 2025. The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient's 3-Lead electrocardiogram acquired from five electrodes. The device is intended for use by adult patients in either a clinical setting or at home. The HeartBeam 12-Lead ECG Synthesis Software synthesizes a 12-Lead ECG from the HeartBeam System's 3-Lead recording device, producing a visual 12-Lead ECG representation that is similar, but not identical, to the same leads of a standard diagnostic 12-Lead ECG.

The synthesized 12-Lead ECG output is solely intended for manual assessment of normal sinus rhythm and specific non-life-threatening arrhythmias: sinus arrhythmia, sinus tachycardia, sinus bradycardia, atrial premature complexes, atrial fibrillation, and ventricular premature complex. The software does not conduct cardiac analysis and is not intended to replace a standard 12-Lead ECG. This technology enables remote monitoring capabilities that could significantly impact how cardiac conditions are detected and managed, potentially reducing the need for hospital visits for routine monitoring. The company holds over 20 issued patents related to technology enablement, underscoring the proprietary nature of its innovation. For additional information about the company's technology and developments, visit HeartBeam.com.

The JP Morgan Healthcare Conference serves as a premier platform for medical technology companies to engage with the investment community and potential partners. HeartBeam's presence at this event, following its FDA clearance, positions the company to advance discussions regarding commercialization and co-development opportunities. The planned limited U.S. commercial launch in early 2026 indicates the company's transition from regulatory approval to market introduction. This development matters because it addresses a growing need for accessible cardiac monitoring solutions that can be utilized outside conventional healthcare settings, potentially improving patient outcomes through earlier detection and continuous monitoring of cardiac conditions. The technology's focus on non-life-threatening arrhythmias fills a specific niche in remote patient monitoring, offering physicians a tool for managing chronic conditions more effectively.